WGWenyi Guo

Wenyi Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenyi Guo has a total of 120 co-authors. Here are the top co-authors by number of shared publications:

  • Yue Wu

    Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    17 shared publications
  • Lulu Huang

    14 shared publications
  • Li Xu

    Department of Ophthalmology, Shanghai 9th People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    13 shared publications
  • Ning Wang

    10 shared publications
  • Yixin Liu

    Department of Ophthalmology, Shanghai 9th People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China

    9 shared publications
  • Hao Sun

    Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China

    8 shared publications

Latest Publications

  • Open Access

    An intelligent systems framework for closed-loop chronic glaucoma management

    by Yiqiao Shi, Hongyi Chai, Yixiong Zhou, Xuefei Song, Wenyi Guo, Weihua Yang, Menghan Hu, Yue Wu

    Background: Glaucoma, the world’s leading cause of irreversible blindness, highlights chronic disease management challenges: fragmented health records, poor adherence, and limited privacy safeguards. While artificial intelligence (AI) shows promise, its clinical application remains confined to isolated algorithmic tasks. Methods: To bridge the gap, GlauHelper, an internet-based platform integrating multiple AI modules, is developed. The dual-end (physician/patient) platform integrates a comprehensive clinical workflow: (1) Secure Data Acquisition, featuring age-friendly interfaces, home-based tonometer, and an image privacy system; (2) Automated Processing Pipeline, which cleans and structures real-world uploads through quality scoring, cascaded classification, and data extraction, with human verification; and (3) Clinical Application, utilizing structured data to drive personalized follow-up, medication tracking, and a domain-specific Large Language Model (LLM) Q&A assistant (“Xiaoqing”) optimized for glaucoma education. Results: Real-world deployment across 30 hospitals and over 10,000 users in China demonstrated high adoption. Experimental validation confirmed the system’s ability to extract structured clinical data, safeguard patient privacy, assess and classify medical images, and deliver educational content. Conclusion: GlauHelper demonstrates the technical feasibility of integrating secure data acquisition, automated information processing, and patient–clinician interaction within a unified glaucoma management workflow. These findings support its preliminary usability and real-world deployability, while its effects on treatment adherence, disease progression, and long-term clinical outcomes require further prospective evaluation.

  • Open Access

    Didymin protects against retinal ischemia–reperfusion injury by suppressing microglial pyroptosis and neuroinflammation via EGFR-mediated NLRP3/GSDMD signaling

    by Chenrui Xu, Ning Wang, Minghan Wang, Lulu Huang, Chengyang Sun, Zhiruo Wang, Tongtong Yan, Mengmeng Xu, Hongyi Chai, Hao Sun, et al.

  • Open Access

    Modifiers of perceived stress in caregivers of children with Sturge-Weber syndrome: a cross-sectional, single-site study

    by Na Du, Junzhao Chen, Hui Wang, Shanshan Xiong, Yue Wu, Wen-Yi Guo, Chang-Juan Zeng

    Background: Sturge-Weber syndrome (SWS), more commonly known as encephalotrigeminal angiomatosis, is characterised by extensive vascular malformations in the face, head, and trunk and glaucoma-induced optic nerve damage, typically on one side, but sometimes involving both sides of the body. As the main caregivers of patients with SWS, caregivers must invest more patience and time into long-term illness and life care. Caregivers’ psychological health, which has been receiving increasing attention from scholars. This study aimed to investigate the status and influencing factors of perceived stress among caregivers of children with SWS and provide a theoretical basis for proposing effective intervention measures. Methods: A total of 105 caregivers of children with SWS treated at a hospital in China were surveyed using general demographic data, the Perceived Stress Scale (PSS-4), the Generalised Anxiety Disorder-7 (GAD-7) Scale, the Patient Health Questionnaire-2 (PHQ-2), and the Simplified Coping Style Questionnaire (SCSQ). Results: Caregivers’ mean total perceived stress score was 7.52±2.14 points. XGBoost and multiple linear regression models were used to analyze the predictors of perceived stress in caregivers of children with SWS and their significance in explaining the variance in perceived stress. The main influencing factors identified were positive coping strategie, anxiety, depression, educational level, child’s gender, perceived disease severity, and methods for detecting eye diseases. Conclusions: Perceived stress among caregivers of children with SWS is influenced by multiple factors. Healthcare professionals should pay attention to these factors and develop effective interventions to reduce caregivers’ perceived stress, promote their physical and mental health, enabling them to provide better care for their children.

  • Open Access

    Tryptophan metabolism in glaucomatous optic neuropathy: from metabolic dysregulation to therapeutic opportunities

    by Ning Wang, Tongtong Yan, Hao Sun, Wenyi Guo

    Glaucoma, a leading cause of irreversible blindness, involves progressive retinal ganglion cell loss. Beyond intraocular pressure, growing evidence implica

  • Open Access

    Extracellular matrix remodeling and endothelial fibrosis in Sturge–Weber syndrome secondary glaucoma: Insights from aqueous humor proteomics

    by Lulu Huang, Minghan Wang, Mengyang Gu, Ning Wang, Chengrui Xu, Mengmeng Xu, Tongtong Yan, Yahan Ju, Dandan Zhang, Yue Wu, et al.


  • Top Cited Papers
    Open Access

    Gut microbiota-derived indoleacetic acid attenuates neuroinflammation and neurodegeneration in glaucoma through ahr/rage pathway

    by Ning Wang, Chengyang Sun, Yijie Yang, Dandan Zhang, Lulu Huang, Chenrui Xu, Minghan Wang, Mengmeng Xu, Tongtong Yan, Yue Wu, et al.

    Gut microbiota has emerged as a promising therapeutic target for neurodegenerative disorders through regulation of neuroinflammatory responses, while its role in optic nerve degeneration remains incompletely characterized. This study elucidates the neuroprotective role of gut microbiota derived tryptophan metabolites in glaucoma through gut-eye communication and inhibition of microglia-mediated neuroinflammation. Gut microbiota profiling (16 S rRNA sequencing) and serum indoleacetic acid (IAA) quantification were performed in glaucoma patients versus controls. Microbiota–metabolite relationships were further validated through fecal microbiota transplantation (FMT). The neuroprotective and anti-neuroinflammatory effect of Bacteroides fragilis (B. fragilis) and IAA was assessed in both microbead-induced ocular hypertension mice model and in vitro BV-2 microglial cell inflammation model via immunofluorescence, qPCR, Western blot and mice behavioral assays. To explore the underlying mechanisms, retinal transcriptomics and microglia-neuron co-cultures were also employed. Glaucoma patients exhibited gut dysbiosis characterized by depleted tryptophan-metabolizing bacteria (B. fragilis, Bacteroides thetaiotaomicron, Anaerostipes hadrus) and reduced serum IAA levels. Mice receiving FMT from glaucoma patients exhibited lower systemic IAA levels. In in vivo and in vitro models, B. fragilis or IAA restored AhR activation, suppressed inflammation by inhibiting microglial activation and the release of pro-inflammatory mediators throughout the retina, reduced retinal ganglion cells (RGCs) loss and preserved visual function. Mechanistically, IAA attenuated RAGE/NF-κB pathway activation via AhR-dependent signaling, conferring neuroprotection. Our study proposes a novel AhR-mediated gut microbiota-eye axis in glaucoma pathogenesis and demonstrates that IAA serves as an effective neuroprotective strategy with clinical potential for managing RGCs neurodegeneration.


  • Open Access

    High burden of blindness at initial hospitalisation with primary angle-closure glaucoma in a national multicentre study in China

    by Kun Xiong, Huiyan Mao, Jinyuan Chen, Qi’aO Zhang, Xue Yin, Dan Wang, Hong Sun, Xiaoli Xing, Guoping Duan, Zhiyang Jia, et al.

    Objective: To determine the prevalence and risk factors for blindness at initial hospitalisation with primary angle-closure glaucoma (PACG) and proposed glaucoma surgery in China. Methods: A multistage stratified sampling method was used to select patients with PACG (1 January 2011 to 31 December 2020) presenting for initial hospitalisation from hospitals of various levels (n=26): 2 nationally leading ophthalmic hospitals, 12 university-affiliated and provincial people’s hospitals and 12 city-level hospitals. Blindness is defined according to WHO standards, with visual acuity 80 years (OR=4.21, 95% CI 3.09 to 5.73) had a higher risk of either-eye blindness compared with those aged 50–59, higher intraocular pressure (IOP; OR=1.06 per mm Hg, 95% CI 1.05 to 1.07), residence in rural areas (OR=1.45, 95% CI 1.24 to 1.70) and presentation to city-level hospitals (vs higher-level facilities, OR=1.53, 95% CI 1.18 to 2.00) increased risk. Similar results were obtained for bilateral blindness. Conclusions: In China, two out of every five PACG patients presenting for initial hospitalisation experienced blindness in at least one eye. Efforts to reduce this burden should focus on improving diagnostic and treatment services at city-level facilities in rural settings while focusing on older patients presenting with higher IOP.


  • Open Access

    Gut microbiota compositional profile in patients with posner-schlossman syndrome

    by Ning Wang, Chengyang Sun, Yahan Ju, Lulu Huang, Yixin Liu, Mengyang Gu, Chenrui Xu, Minghan Wang, Yue Wu, Dandan Zhang, et al.


  • GNAQ R183Q somatic mutation contributes to aberrant arteriovenous specification in Sturge–Weber syndrome through Notch signaling

    by Lulu Huang, Hao Sun, Yixin Liu, Li Xu, Menghan Hu, Yijie Yang, Ning Wang, Yue Wu, Wenyi Guo

    Episcleral vasculature malformation is a significant feature of Sturge–Weber syndrome (SWS) secondary glaucoma, the density and diameter of which are correlated with increased intraocular pressure. We previously reported that the GNAQ R183Q somatic mutation was located in the SWS episclera. However, the mechanism by which GNAQ R183Q leads to episcleral vascular malformation remains poorly understood. In this study, we investigated the correlation between GNAQ R183Q and episcleral vascular malformation via surgical specimens, human umbilical vein endothelial cells (HUVECs), and the HUVEC cell line EA.hy926. Our findings demonstrated a positive correlation between episcleral vessel diameter and the frequency of the GNAQ R183Q variant. Furthermore, the upregulation of genes from the Notch signaling pathway and abnormal coexpression of the arterial marker EphrinB2 and venous marker EphB4 were demonstrated in the scleral vasculature of SWS. Analysis of HUVECs overexpressing GNAQ R183Q in vitro confirmed the upregulation of Notch signaling and arterial markers. In addition, knocking down of Notch1 diminished the upregulation of arterial markers induced by GNAQ R183Q. Our findings strongly suggest that GNAQ R183Q leads to malformed episcleral vasculatures through Notch‐induced aberrant arteriovenous specification. These insights into the molecular basis of episcleral vascular malformation will provide new pathways for the development of effective treatments for SWS secondary glaucoma.